Development of the Enabling Route for Glecaprevir via Ring-Closing Metathesis

Glecaprevir was identified as a potent HCV NS3/4A protease inhibitor, and an enabling synthesis was required to support the preclinical evaluation and subsequent Phase I clinical trials. The enabling route to glecaprevir was established through further development of the medicinal chemistry route. T...

Full description

Saved in:
Bibliographic Details
Published in:Organic process research & development 2020-02, Vol.24 (2), p.183-200
Main Authors: Cink, Russell D, Lukin, Kirill A, Bishop, Richard D, Zhao, Gang, Pelc, Matthew J, Towne, Timothy B, Gates, Bradley D, Ravn, Matthew M, Hill, David R, Ding, Chen, Cullen, Steven C, Mei, Jianzhang, Leanna, M. Robert, Henle, Jeremy, Napolitano, José G, Nere, Nandkishor K, Chen, Shuang, Sheikh, Ahmad, Kallemeyn, Jeffrey M
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Glecaprevir was identified as a potent HCV NS3/4A protease inhibitor, and an enabling synthesis was required to support the preclinical evaluation and subsequent Phase I clinical trials. The enabling route to glecaprevir was established through further development of the medicinal chemistry route. The key steps in the synthesis involved a ring-closing metathesis (RCM) reaction to form the 18-membered macrocycle and a challenging fluorination step to form a key amino acid. The enabling route was successfully used to produce 41 kg of glecaprevir, sufficient to support the preclinical evaluation and early clinical development.
ISSN:1083-6160
1520-586X
DOI:10.1021/acs.oprd.9b00469